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Abstract
Hepatitis delta virus (HDV) increases morbidity in Hepatitis B virus (HBV)-infected patients.
In the mid-eighties, an outbreak of HDV fulminant hepatitis (FH) in the Central African
Republic (CAR) killed 88% of patients hospitalized in Bangui. We evaluated infections with
HBV and HDV among students and pregnant women, 25 years after the fulminant hepatitis
(FH) outbreak to determine (i) the prevalence of HBV and HDV infection in this population,
(ii) the clinical risk factors for HBV and/or HDV infections, and (iii) to characterize and com-
pare the strains from the FH outbreak in the 1980s to the 2010 HBV–HDV strains. We per-
formed a cross sectional study with historical comparison on FH-stored samples (n = 179)
from 159 patients and dried blood-spots from volunteer students and pregnant women
groups (n = 2172). We analyzed risk factors potentially associated with HBV and HDV.
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Previous HBV infection (presence of anti-HBc) occurred in 345/1290 students (26.7%) and
186/870 pregnant women (21.4%)(p = 0.005), including 110 students (8.8%) and 71 preg-
nant women (8.2%), who were also HBsAg-positive (p = 0.824). HDV infection occurred
more frequently in pregnant women (n = 13; 18.8%) than students (n = 6; 5.4%) (p = 0.010).
Infection in childhood was probably the main HBV risk factor. The risk factors for HDV infec-
tion were age (p = 0.040), transfusion (p = 0.039), and a tendency for tattooing (p = 0.055)
and absence of condom use (p = 0.049). HBV-E and HDV-1 were highly prevalent during
both the FH outbreak and the 2010 screening project. For historical samples, due to storage
conditions and despite several attempts, we could only obtain partial HDV amplification rep-
resenting 25% of the full-length genome. The HDV-1 mid-eighties FH-strains did not form a
specific clade and were affiliated to two different HDV-1 African subgenotypes, one of which
also includes the 2010 HDV-1 strains. In the Central African Republic, these findings indi-
cate a high prevalence of previous and current HBV-E and HDV-1 infections both in the mid-
eighties fulminant hepatitis outbreak and among asymptomatic young adults in 2010, and
reinforce the need for universal HBV vaccination and the prevention of HDV transmission
among HBsAg-positive patients through blood or sexual routes.
Author summary
In the Central African Republic (CAR), due to 20 years of conflict, the health system has
been disorganized. This could contribute to maintenance of high transmission levels of
Hepatitis B Virus (HBV) and its satellite Hepatitis Delta Virus (HDV). This work studies
the evolution of both infections 25 years after a fulminant hepatitis (FH) outbreak occur-
ring in the mid-1980s associated with HDV superinfection. In young asymptomatic
adults, the results show that both HBV and HDV were still actively circulating in CAR in
2010. Indeed, more than one third of HBV-infected individuals were chronic HBV carri-
ers. Furthermore, HDV infection could be spreading among 10% of them through blood
and sexual transmission. The past FH outbreak and contemporary infections were both
associated with heterogeneous HDV-1 strains, combined with HBV-E. Vaccination
against HBV was uncommon among pregnant women and students, even among medical
students. The study constitutes warning signals to help CAR health-care reconstruction
and underlines the importance of HBV vaccination. The high level of HBV infection cre-
ates a background for HDV superinfection. Neonatal HBV vaccination is needed, together
with vaccination of unprotected populations. Awareness of health authorities as well as
the general public would help reduce HBV and HDV infections.
Introduction
Hepatitis B virus (HBV) infection can be prevented by vaccination, which can obviate progres-
sion of chronic liver disease to cirrhosis, liver failure and hepatocellular carcinoma. However,
owing to limited access to vaccination during the past 30 years in resource-poor countries,
more than 2 billion people have been infected with HBV and approximately 257 million
remain chronic carriers, especially those infected at birth or in early childhood [1].
Viral hepatitis can be associated with acute severe illness, sometimes leading to fulminant
destruction of the liver parenchyma or to chronic inflammatory-based injury, resulting in liver
HBV and HDV in CAR
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remodeling and regeneration that contributes to fibrosis and early carcinogenic events. Both
acute co-infection with HBV and hepatitis D virus (HDV) and superinfection of chronic HBV
carriers by HDV can aggravate these clinical spectra [2,3], sometimes leading to fulminant
hepatitis (FH) at higher rates than in HBV monoinfection. In the early years after HDV discov-
ery, HDV co- and super-infection profiles accounted respectively for 58% and 42% of delta-
associated FH in Western Europe [4]. Furthermore, liver fibrosis accelerates in chronic HBV
and HDV infections and HDV may have a role in carcinogenesis [5, 6]. A recent meta-analysis
studying the prevalence of HDV infection in Sub-Saharan countries indicated that in countries
surrounding CAR, such as Cameroon, anti-HD Ab prevalence was up to 14% of HBsAg-posi-
tive individuals from a national survey [7]. Furthermore, in the Central African Republic
(CAR) among patients followed up in hepatology clinics, the anti-HD prevalence reached 50%
and this prevalence was 18% in patients with HCC [7].
Although HDV was identified only 40 years ago [3], it has probably been present in humans
for a long time. The virus is ubiquitous, and the prevalence of HDV infection among HBsAg-
carriers may vary from 0.5% to 40%, depending of the geographical area studied [2]. A global
estimation of HDV-infected population suggests that 10–20 million HBV-infected people have
encountered HDV. The virus has high genetic variability, especially in Africa, Amazonia and
Asia [8,9]. Currently, the Deltavirus genus comprises eight major clades, or genotypes, labelled
HDV-1 to HDV-8 [9,10]. HDV-1 is ubiquitous while HDV-2 and HDV-4 in Asia and HDV3
in Amazonia are geographically restricted. HDV-5–HDV-8 have a clear African origin but
may be found elsewhere, due to slave trading and human migration [9,11]. While HBV is a
DNA virus with a reverse transcriptase targeted by antiviral drugs, HDV RNA replicates by
hijacking the cellular RNA polymerase II. Therefore, chronic hepatitis due to HBV–HDV is
the most difficult-to-treat of all severe virally-induced liver diseases [12–14]. Even though ther-
apeutics are available for chronic HBV or HCV infections, about 15 million HBV–HDV-
infected patients worldwide await efficient therapy. Alpha-Interferon or Pegylated-IFN that
are currently the sole anti-HDV authorized drugs, may be of limited efficacy in less than one
third of infected patients. Furthermore, addition of Adefovir or Tenofovir or Entecavir to
Pegylated-IFN does not improve the sustained response rate among HDV-1-infected patients,
underlining the importance for developing new approaches [12,14]. Indeed, new strategies,
such as viral entry competitors, farnesyl transferase inhibitors and nucleic acid polymers are
nowadays promising, even if they are still upstream from a wide clinical use [14].
The severity of HBV–HDV infections could be due to particular evolutionary and/or geo-
graphical combinations of HBV–HDV genotypes, and some HBV–HDV pairs may be more
pathogenic than others [15,16]. In the mid-1980s, cases of severe acute liver failure in Bangui,
Central African Republic (CAR), were associated with an HDV outbreak. At least 124 cases of
FH occurred among 154 cases of jaundice at Bangui University Hospital, and 88% of the
patients died [17]. The evolution of HDV has not been studied since the outbreak, although
the high prevalence of HBV infection [18] and the global instability in CAR constitute a poten-
tial background for the spread of HDV that may lead to severe chronic liver disease and
increased risk of dying from liver failure. Furthermore, although a national HBV preventive
program is still conducted, the civil war in the country might have maintained high levels of
HBV and HDV transmission through injuries, blood and sexual contacts, mother-to-child
transmission and even unsafe blood transfusion. Indeed, viral hepatitis infections, especially
hepatitis B, are likely to continue to be a major problem in the near future in CAR. Therefore,
it seems crucial to reappraise the level of HBV and HDV infection in young CAR patients to
specify the level of unprotected persons that may benefit from catch-up vaccination, if they are
free of infection, and those that might be included in future therapy protocols at a time where
HBV and HDV in CAR
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the World Health Organisation reflexion encourages specific hepatitis funding among infec-
tious diseases global health strategies.
The aims of our study were (i) to determine the prevalence of HBV and HDV infection in
young asymptomatic students and pregnant women born at the end or after the end of the FH
outbreak, (ii) to determine possible clinical risk factors for HBV and/or HDV infections in this
population and (iii) to characterize and compare the strains from the FH outbreak in the
1980s to 2010 HBV–HDV strains.
Methods
We performed a cross sectional study with historical comparison.
Prospective study population
Two cohorts, volunteer students (n = 1298) and pregnant women (n = 874), were prospectively
sampled between January and December 2010 (S1 Method and S1 Table). Based on volunteer-
ing, students came from almost all public and private high schools in Bangui, the capital of
CAR, and all different departments of the University of Bangui (S2 Table). Objectives of the
study were carefully explained to high-school directors and to the university general secretary
in order to obtain authorisation. The investigators then organized information meetings in
each secondary school and faculty before distributing the information notice. Written consent
forms were obtained from those who freely accepted to participate to the study. Therefore, this
recruitment should be considered as passive. Interested students filled the questionnaire anon-
ymously. Recruitment of pregnant women (PW) was performed in all public health structures
(n = 6) with maternity wards in Bangui. In these places, medical staffs, including qualified mid-
wives involved in the Mother-to-Child HIV transmission prevention (MCTP), were responsi-
ble for sampling. PW coming for prenatal consultation were sampled (dried blood spot) after
an initial pre-test counselling. All consecutive pregnant women that accepted to participate to
the study signed the consent form and answered the epidemiological questionnaire. Those
who had an HBsAg positive result were then followed at the 2 reference public hospitals:
“Communautaire” and “l’Amitie´”, under the supervision of one of us (AS). No recruitment
occurred in private clinics. In all, 874 consecutive pregnant women agreeing to participate
were included. The information asked for all participants included gender, age, place of living
in Bangui, occupation, marital status, personal viral hepatitis history and previous HBV vacci-
nation. Risk factors investigated were surgery, dental extraction, blood transfusion, IVDU, tat-
tooing, use of sharp tool, alcohol intake and sexual risk factors including ancient and actual
sexual partners and use of condom (S1 Method: French-to-English translated questionnaire).
Ethical approval
The study protocol was approved by the Scientific Committee of the Faculty of Medicine
(CSVPRS, 12/2009; University of Bangui, CAR) and by a French ethical committee
(CCPPRB, CPP 09024/2009; Saint-Germain-en-Laye, France) under ANRS guidelines.
Written informed consent was obtained from all participants. For subjects under 18, paren-
tal consent was obtained. Each participant or parent was individually informed of the results
of the serological tests.
Samples
1984–1987 outbreak: Archived samples had been conserved in a cold room (–20˚C) in Lyon,
France, since the FH outbreak [17]. For HBsAg serological studies, we used 179 serum samples
HBV and HDV in CAR
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from 159 individuals, including patients and close relatives or health-care workers (HCWs),
sampled at the same time. Because of insufficient volumes, we conducted molecular analyses
for only 133 samples from FH patients and close relatives or HCWs. However, we could not
distinguish between these categories because the identifiers were no longer available.
Specimen collection in 2010: Dried blood spots (n = 6/individual) were prepared as described
previously [18]. Filter papers were sealed and stored at the Institut Pasteur de Bangui at –20˚C
with desiccant until serological assay. To ensure enough sample for molecular analyses of HBV
and HDV, 10 mL of total blood were taken from the HBsAg-positive volunteer students (see
below) and conserved at –80˚C.
Serological assays
Dried blood spots were examined as described previously [18]. All three markers HBsAg, anti-
HBc and anti-HBs tests (Abbott-Murex, United Kingdom) were performed according to the
manufacturers’ instructions in 2160 individuals’samples. HBsAg-positive results were con-
firmed in the Murex HBsAg Confirmatory test, Version 3. HBsAg-positive samples from the
1985 (n = 84) and 2010 (n = 181) serum collections were screened for HDV with the anti-
HDV total antibody test and HDAg detection tests (diaSorin, Italy).
HBV and HDV viral loads and sequence analysis
From the 114 HBsAg-positive students contacted, 82 individuals agreed to give serum samples
for molecular analyses, including all HDV-infected students. Studies were performed at the
University Paris 13, Bobigny, France, as previously described [19,20].
Archived sample extraction and amplification
To avoid contamination with recent samples, archived samples were extracted and amplified
in a separate laboratory in Lyon, France. Initially, Macherey-Nagel extraction procedures were
used for 40 samples using RNA and DNA extraction kits to explore both HBV and HDV geno-
types, respectively. For subsequent samples, due to the conservation conditions, all efforts
were focused on HDV RNA detection and characterization. Total nucleic acids were extracted
by an automated procedure (VERSANT1 kPCR, Siemens Healthcare). Control water extrac-
tion was included for every 10 samples. A 400 base pair HDV fragment was amplified accord-
ing to reference [9]. (dx.doi.org/10.17504/protocols.io.mtdc6i6) with HiFi Kapa polymerase
(KapaBiosystems). This RT-PCR procedure has been shown to be of higher sensitivity than the
RT-qPCR approach [21] and was chosen to minimize the risk of underestimation of the results
because of the sub-optimal conservation conditions of the historic samples (-20˚C during 25
years). To amplify the full-length L-HD gene, we designed a 5’ primer corresponding to the
seven first codons of HDV-1 sequences. For HBV genotyping, PreS1 and PreC-C genes were
amplified according to [19] (dx.doi.org/10.17504/protocols.io.m8jc9un and dx.doi.org/10.
17504/protocols.io.mixc4fn, respectively). Unfortunately, despite many attempts, full-length
sequence analysis of mid-eighties FH-associated strains was unsuccessful. Sequence analysis
and phylogenetic studies were conducted with different models and Bayesian reconstruction,
as described previously [9,10,20].
Statistical analysis
Sample size was calculated with the following formula taking into account potential cluster
effects:
HBV and HDV in CAR
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N0 = Dz
2pq/i2 where N0 is the sample size, p the expected HBV prevalence, q = 1-p, D the
cluster effect (set at 1), and i the acceptable precision (set at 2%). Considering a theoretical
HBsAg prevalence among students of 15% [18], the calculated sample size is 1257 (z = 1.96).
For pregnant women, the required sample size based on a theoretical prevalence of 13% is 1087.
Results are presented as numbers and percentages for qualitative variables, and as means +/-
standard deviations (SD) for quantitative variables.
Pearson Chi-squared or, when necessary, Fisher exact tests were used to compare categori-
cal data between the different groups. For continuous data, Student’s t test was used. Multivari-
ate analysis using logistic regression was performed to identify factors potentially associated
with HDV. A p value <0.05 was considered statistically significant. Statistical analyses were
performed using SPSS for Windows Version 19.0 (IBM Corp., Armonk, NY, USA).
Results
HDV serological assay results in the historical cohort
Among the 159 individuals, identifiers of their status such as health care worker were no lon-
ger available, although four family clusters (n = 6, 6, 2, 2 members, respectively) could be dis-
tinguished. Therefore, to study hepatitis delta markers, we retrospectively focused on samples
having an HBsAg positive result (n = 94 patients). For 84 of them (89.4%), both HDAg and
total anti-HD Ab were tested using commercial ELISA tests. Results are described in Table 1.
HDAg and anti-HD total Ab tests were both positive in 4/84 samples, HDAg was the only posi-
tive delta marker in 24/84 samples and anti-HD total Ab was the only marker in 23/84 samples,
making 51/84 (60.7%) samples that had at least one positive HDV serological marker. These
results are to be regarded in the context of the fulminant acute HDV/HBV outbreak, at a time
when anti-HD Abs could not be detectable in a large number of samples corresponding to
Day1, Day2 or Day3 of the severe acute liver disease.
Table 1. Prevalence of HBV and HDV markers in 2172 young asymptomatic adults (students and pregnant women) in Bangui (CAR), in year 2010. Historical
cohort (n = 159) corresponds to -20˚C cryopreserved serum from a hepatitis delta fulminant outbreak and control samples collected in the mid-eighties. Data are mean
(SD), or n (%) unless otherwise stated. ND, not determined.
Prospective cohort (n = 2172) Students (n = 1298) Pregnant women (n = 874) Total (n = 2172) P1 Historical cohort (n = 159)
Age (mean ± SD) (n = 2170) 21.9 ± 4.0 25.0 ± 5.7 23.1 ± 5.0 <0.001 ND
Sex (F/M) (n = 2170) 448/848 874/0 1322/848 <0.001 ND
Previous vaccination (n = 2165) 20 (1.5%) 23 (2.6%) 43 (2.0%) 0.074 ND
HBsAg positive2 (n = 2160) 110 (8.5%) 71 (8.2%) 181 (8.4%) 0.824 94/154 (61.3%)
Anti-HBc IgG positive (n = 2160) 345 (26.7%) 186 (21.4%) 531 (24.6%) 0.005 ND
Anti-HBc IgG positive among HBsAg negative
(n = 1979)
235 (19.9%) 115 (14.4%) 350 (17.7%) 0.002 ND
HBsAg and/or anti-HBc IgG positive (n = 2160) 345 (26.7%) 186 (21.4%) 531 (24.6%) 0.005 ND
Anti-HDV Ab positive3 5/110 (4.5%) 13/69 (18.8%) 18/179 (10.0%) 0.004 27/844 (32.1%)
HDAg positive3 1/110 (0.9%) 0/69 (0.0%) 1/179 (0.5%) 1.000 28/844 (33.3%)
HDV infection3,5 6/110 (5.4%) 13/69 (18.8%) 19/179 (10.6%) 0.010 51/845 (60.7%)
1Comparison Students versus Pregnant Women
2Five students among 2165 having HBsAg positive results did not have anti-HBc testing and were discarded from this analysis
3Among 179 recent HBsAg-confirmed positive results
4Due to insufficient serum volumes HDV serological tests were performed on 84/94 HBsAg-positive historical samples. Four patients had both HDAg and anti-HD Ab
positive results
5Considering positive Anti-HDV Ab and/or positive HDAg results
https://doi.org/10.1371/journal.pntd.0006377.t001
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Prospective 2010 survey
HBV infection was highly prevalent in this highly-educated young asymptomatic population.
When anti-HBc was used as a marker of previous HBV infection among 2160 individuals, 345
students (26.7%) and 186 pregnant women (21.4%) had encountered HBV at some time
(Table 1). HBsAg was present in samples from 110 students (8.5%) and 71 pregnant women
(8.2%) (p = 0.824) (Table 1). Of the 531 subjects positive for anti-HBc, 181 (110 + 71) had
HBsAg detectable in their serum, indicating a high chronicity rate of 34.1%. As the risk of
becoming a chronic carrier is higher in young children than in adolescents or adults and
because no significant known adult risk factors of transmission emerged when comparing
HBV-positive versus HBV-negative individuals (Table 2 and S3 Table and S4 Table), this result
may indicate that possible major routes for HBV infection were (i) being born from an
HBsAg-positive mother or (ii) being infected in the very first years of life. To avoid confound-
ing factors, each cohort was also studied specifically comparing the HBV-non infected versus
the HBV-infected individuals (S5 Table and S6 Table). Age was slightly significantly associated
to HBV previous or current infection in students, whereas previous hepatitis and alcohol
intake were identified as risk factors in the pregnant women group.
HDAg and total anti-HD (IgM/IgG) were studied in sera from 110/110 (100%) HBsAg-
positive students and 69/71 (97.2%) HBsAg-positive pregnant women. Five students and 13
pregnant women had anti-HD antibodies in their serum, and one student, without detect-
able anti-HD, had a positive HDAg result thus considered to have acute hepatitis D. There-
fore, the prevalence of HDV infection was 6/113 students (5.4%) and 13/69 pregnant
women (18.8%). Indeed, whereas HBsAg prevalence was similar between the two groups,
HDV prevalence was significantly higher among pregnant women than students (Table 1,
p = 0.010). The possible contributing factors for HDV acquisition were a higher mean age
(p<0.001), higher rates of previous blood transfusion (p< 0.039) and tattooing (p<0.055)
and a lower rate of condom use (p = 0.049) (Table 3). Concerning this last point, we could
not rule out a confounding factor as pregnant women obviously did not always have con-
dom-protected sex and were significantly more frequently infected with HDV than stu-
dents. On the other hand, we cannot exclude age as an HDV increased risk factor, as this
was found, although non significantly, in each cohort considered independently (S7 Table
and S8 Table). Because the end of the fulminant hepatitis outbreak occurred late 1987, older
students and pregnant women would have been born when HDV transmission risk was still
present.
HBV DNA amplification and sequencing
Nucleic acid testing for HBV sequences was achievable for 40 historical samples with sufficient
residual volume, and the Pre-C/C region of HBV could be amplified and sequenced from eight
samples. Seven sequences were of HBV genotype E and one of genotype A2 (S1A Fig). For the
contemporary survey, of the 110 HBs-Ag positive students, 82 (71.9%) agreed to return for
medical examination and virus analyses. The HBV DNA viral loads were quantified, except for
two samples, in which amplification failed. In the 80 remaining samples, HBV-DNA was
undetectable in seven (8.75%), at a low level (< 3.3 log10 IU/mL) in 33 (41.25%) at a medium
level (> 3.3< 8.3 log10 IU/mL) in 18 (22.5%) and at a high level (> 8.23 log10 IU/mL) in 22
(27.5%), indicating that half of the asymptomatic students had moderate-to-high viral replica-
tion. Amplification of the Pre-S1 coding region of the HBV genome resulted in 50 interpret-
able HBV sequences that were submitted to Bayesian analyses with reference sequences (S2A
Fig). Tree reconstruction indicated that most of CAR2010 were of HBV genotype E (n = 48)
whereas 2 CAR2010 strains corresponded to HBV_DE recombinants (S2A Fig and S1B Fig
HBV and HDV in CAR
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and S2B Fig). In addition, we then aimed to amplify the PreC/C from 2010 CAR HBV strains
and obtained 35 sequences all affiliated to HBV genotype E (S1B Fig). We also tried to amplify
the Pre-S1 coding region from the 40 HBsAg positive historical samples for which DNA had
been extracted, focusing on HBsAg-positive ones. We could obtain 5 Pre-S1 sequences corre-
sponding to 3 patients with fulminant hepatitis (HF2, HF19 and HF27). Tree reconstruction,
focused on HBV D and E genotypes, indicates that all three FH-associated HBV strains corre-
sponded to HBV_E genotype and one of them could cluster with one CAR2010 HBV strain
(S2B Fig).
Table 2. Comparison of HBV status among young asymptomatic adults (students and pregnant women) in Bangui, Central Africa Republic (CAR) in 2010.
Anti-HBc antibodies
AND/OR HBsAg
Negative
(n = 1631)
Positive
(n = 531)
p
Group Students (n = 1296) 947 (73.1%) 349 (26.9%) 0.002
Pregnant Women (n = 866) 684 (79.0%) 182 (21.0%)
Age (years; mean ± SD) 23.1 ± 5.0 23.3 ± 5.0 0.456
Female:male 997:634 317:214 0.558
Marital status (n/%) 0.156
Single 1378 (84.5%) 454 (85.5%)
Live-in partnership 133 (8.2%) 50 (9.4%)
Married (monogamous) 89 (5.5%%) 18 (3.4%)
Married (polygamous) 29 (1.2%) 7(1.3%)
Widowed 2 (0.1%) 2 (0.4%)
District Address in Bangui See details in S3 Table 0.769
Occupation See details in S4 Table 0.600
CAR nationality 1620 (99.3%) 526 (99.1%) 0.561
Risk factors Previous viral hepatitis
(n = 2045)
27 (1.8%) 15 (3.0%) 0.094
Previous icterus
(n = 2148)
132 (8.2%) 55 (10.4%) 0.112
Surgery
(n = 2162)
126 (7.7%) 44 (8.3%) 0.677
Dental extraction
(n = 2155)
491 (30.2%) 138 (26.1%) 0.080
Blood transfusion
(n = 2152)
75 (4.6%) 26 (4.9%) 0.874
Tatoo
(n = 2162)
102 (6.3%) 35 (6.6%) 0.782
Intravenous drug user
(n = 2162)
8 (0.5%) 3 (0.6%) 0.531
Sharp-edged tool use
(n = 2162)
851 (52.2%) 270 (50.8%) 0.594
Alcohol
(n = 2162)
784 (48.1%) 264 (49.7%) 0.509
Multiple partners before
(n = 2162)
579 (35.5%) 201 (37.9%) 0.327
Multiple partners in 2010
(n = 2162)
98 (6.0%) 35 (6.6%) 0.627
Use of condom-(n = 2075) Always 414 (26.4%) 147 (29.0%) 0.045
sometimes 375 (23.9%) 140 (27.6%)
never 779 (49.7%) 220 (43.4%)
Previous HBV vaccination (n = 2156) 31 (1.9%) 11 (2.1%) 0.801
https://doi.org/10.1371/journal.pntd.0006377.t002
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HDV RNA amplification and sequencing
Among 88 of the 94 HBsAg-positive historical samples (Table 1) that were available for HDV
molecular studies, a 400-bp target encompassing the 3’ coding region of the LHD gene was
successfully amplified, cloned and sequenced from 12 HDV-infected patients. Full-length
LHD gene amplification from historical samples was successful in only three cases, although
several clones were sequenced from each. For the 2010 samples from the 6 HDV-positive stu-
dents, the 400-bp target could be amplified in five cases from both serum and dried blood spot
and from serum only in one case. All sequences from historical and contemporary samples
were unambiguously belonging to the HDV-1 genotype (Fig 1). A Bayesian reconstruction
consensus tree, obtained using CAR historical and contemporary sample sequences from this
study, African (Cameroon, CAR, Chad, Coˆte d’Ivoire) sequences (S9 Table), and sequences
retrieved from databases, is displayed in Fig 1. The database sequences included the eight
HDV genotype-prototype sequences (shown in red in Fig 1) and other HDV-1 CAR sequences
characterized in 2009 [22].
The topology of the tree clearly indicates that the FH viral sequences do not form a specific
historical clade. Thus, all HDV sequences from the HF-mid-eighties strains did not derive
Table 3. Comparison of HDV status among 182 HBsAg-positive young asymptomatic adults (students and pregnant women) in Bangui, Central Africa Republic
(CAR) in 2010.
HDV (Anti-HD
AND/OR HDAg)
Negative (n = 163) Positive (n = 19) p
Group Students (n = 113) 107 (94.7%) 6 (5.3%) 0.004
Pregnant Women (n = 69) 56 (81.2%) 13 (18.8%)
Age (years; mean) [SD] 23.30 ± 5.09 25.89 ± 5.76 0.040
Female:male 103/60 17/2 0.022
Marital status (n/%) 0.736
Single 139 (85.3%) 16 (84.2%)
Live-in partnership 15 (9.2%) 2 (10.5%)
Married (monogamous) 5 (3.1%)/ 1 (5.3%)/
Married (polygamous) 2 (1.2%) 0 (0.0%)
Widowed 2 (1.2%) 0 (0.0%)
District Address in Bangui See S3 Table 0.165
Occupation See S4 Table 0.067
CAR nationality 160 (98.2%) 18 (94.7%) 0.359
Risk factors Previous viral hepatitis (n = 174) 5 (2.6%) 2 (10.5%) 0.170
Previous icterus (n = 182) 15 (8.2%) 2 (10.5%) 0.553
Surgery (n = 182) 12 (6.6%) 1 (5.3%) 0.596
Dental extraction (n = 182) 40 (22.0%) 8 (42.1%) 0.100
Blood transfusion (n = 182) 5 (2.7%) 3 (15.8%) 0.039
Tatoo (n = 182) 11 (6.0%) 4 (21.1%) 0.055
Intravenous drug user (n = 182) 1 (0.5%) 0 (0.0%) 0.896
Sharp-edged tool use (n = 182) 85 (46.7%) 8 (42.1%) 0.407
Alcohol (n = 182) 81 (44.5%) 10 (52.6%) 0.808
Multiple partners before (n = 182) 67 (36.8%) 6 (31.6%) 0.423
Multiple partners in 2010 (n = 182) 13 (7.1%) 1 (5.3%) 0.557
Use of condom:- always 43 (27.0%) 5 (26.3%) 0.049
(n = 178) - sometimes 47 (29.6%) 1 (5.3%)
- never 69 (43.4%) 13 (68.4%)
Previous HBV vaccination (n = 181) 0 (0.0%) 1 (5.3%) 0.105
https://doi.org/10.1371/journal.pntd.0006377.t003
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Fig 1. Phylogenetic analysis of HDV partial genome (400 bp) comparing mid-eighties delta fulminant hepatitis
clones (FH1985) to HDV direct sequences (CAR2010) sampled in 2010 from serum (s) and dry blood spot (d) among
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from a common ancestor in a single phylum, unrelated to the recent HDV sequences retrieved
from asymptomatic students. Instead, one large clade intercalates historical and recent
sequences from our study in CAR, plus other Central and West African HDV-1 strains, and
sequences from Ethiopia, Somalia and Lebanon characterised previously. Inside this clade,
there is one strong sustained branch (posterior probability (pp) = 0.99) that includes four FH
strains (FH12, FH82, FH88 and FH123) and sequences from strains that infect patients in
CAR and Chad. All the other FH strain sequences cluster (pp = 1) with isolates from patients
originating from CAR, Cameroon, Coˆte d’Ivoire and Lebanon. Among HDV-1 strains, recent
full-length HDV genome analyses have raised the possibility of the existence of at least 4 HDV
subgenotypes [23]. Even if we could only obtain partial sequences due to conservation condi-
tions, we reanalysed the HDV sequences and conclude that FH12, FH82 FH88 and FH123
were clearly affiliated to the suggested HDV-1a (Ancestral African) subgenotype. In contrast,
the other ancient and recent trains clustered together with the Lebanon strain suggesting that
they corresponded to HDV-1b subgenotype stains. Although a formal analysis should have
included full- length sequences, these results reinforce the fact that the fulminant hepatitis out-
break in the mid-eighties was linked to very different HDV-1 strains. Translation of the coding
region for the C-terminus of HDAg showed a serine residue at position 202 in all sequences
(Fig 2), corroborating an African HDV-1 affiliation [20]. FH27 isolate clone 4 sequence had a
nucleotide deletion leading to a frameshift mutation in the L-HDAg sequence that abrogates
the farnesylation signal. Otherwise, the comparison of L-HDAg amino acid sequences from
historical FH samples with recent samples revealed no specific FH-associated signature.
Discussion
To study the persistence of hepatitis B and hepatitis Delta viruses twenty-five years after a
major HDV and HBV FH outbreak in an equatorial city in Africa, we conducted a prospective
search among young healthy adults in 2010. The study was not designed to specify HBV and
HDV prevalence in extensive Bangui populations, but was focused on individuals born at or
after the end of the epidemic outbreak, to assess viral long-term continuance. After patient
inclusion, questionnaire filling and screening, further actions included volunteer-based HBV
vaccination and medical examination, for seronegative individuals and HBsAg-positive carri-
ers, respectively.
An important observation is that both HBV and HDV are still actively circulating in CAR.
Indeed, both students and pregnant women had a high prevalence of previous HBV infection
and HBsAg-chronic carriage. In this survey, including a highly educated population, more
than one third of HBV-infected individuals were chronic carriers. It has been estimated that
90% of newborns infected at or shortly after birth will become HBV carriers, although this rate
decreases with age, until less than 5–10% for adolescent or adult HBV-infections [24]. In this
study, most of the students and pregnant women who were anti-HBc-positive had probably
been infected at an early age, indicating the importance of sustaining an anti-HBV vaccine
asymptomatic young adults in Bangui. We aligned 45 cloned sequences from the 12 FH strains obtained from the
historical cohort (labelled ‘1985’ in green) and the 6 strains obtained from asymptomatic students in 2010 represented in
duplicate from serum (s) and dried blood (d) (labelled ‘2010’ in blue). We also included 1 strain from a hospitalized case of
acute HDV hepatitis in Bangui in 2010 (sd525-CAR2010) and HDV-1 sequences from 9 African samples characterized in
Bobigny (dFr) or Lyon (dLy), France, in addition to CAR HDV sequences published by Andernach and coworkers [22],
sampled in 2009. Further comparison included HDV strains from various parts of the world and genotype-reference
prototypes (labelled in red). Bayesian analyses (10M generations) gave the consensus tree represented in Fig 1, after
discarding 25% of trees from early topology exploration. Branch values indicate posterior probabilities>0.9. Interestingly,
the fulminant 1985 and asymptomatic student 2010 strains are all affiliated to HDV-1 with a 100% posterior probability
value (thick branch) and the clade topology do not distinguish the mid-eighty strains from the 2010 strains.
https://doi.org/10.1371/journal.pntd.0006377.g001
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strategy for newborns in CAR. Furthermore, HDV could be amplified from all six students
with anti-HD or HDAg, indicating continuing HDV replication and an active reservoir that
also could have been prevented by early anti-HBV vaccination. Indeed, an important issue cor-
responds to the fact that a very low prevalence of earlier anti-HBV vaccination (<2%) was
observed and that a failure for students to participate for a de novo free anti-HBV vaccination
was evidenced, both indicative of HBV (and HDV) potential acquisition in adulthood.
HDV infection was still active in 2010 cohorts, however, due to our study design focused on
asymptomatic young adults, no fulminant hepatitis was observed in 2010 infections. By com-
parison, a study conducted in the Democratic Republic of Congo revealed than HBV-HDV
could be found in 26.1% of acute febrile jaundice samples from a national yellow fever survey
from 2003 to 2011 [25].
In CAR, HBV-E and HDV-1 were present in the 1980s and 2010 and no specific fulminant
hepatitis-associated HDV strain pattern was clearly evidenced comparing 1980s to 2010
Fig 2. Alignment of the L-HDAg amino acid deduced sequences from fulminant-associated isolates from the historical cohort (1985) and from young
asymptomatic HDV-infected students (2010). The alignment is compared together with L-HDAg sequences from HDV-1 prototype (Italy, Accession
Number:X04451) and HDV-3 prototype (Peru-1, Accession Number:L22063), representing the prototypes of two HDV genotypes associated with
fulminant hepatitis outbreaks. Dots represent the same amino acid as in the Italy prototype and question mark ambiguities. A: Full-length coding sequences
(214 codons) were obtained for 3 FH isolates (FH27, FH88, FH123). B: COOH terminal part of L-HDAg of the corresponding HDV 1985 (45 FH clones)
associated with fulminant hepatitis and 2010 (seven) sequences associated to asymptomatic infections. Note that all the African sequences have the A202S
mutation and that FH27 clone 4 has a frameshift mutation of the carboxy-terminal end of L-HDAg (ORF-K), leading to the disappearance of the
farnesylation CXXX box.
https://doi.org/10.1371/journal.pntd.0006377.g002
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strains. During the FH outbreak in Bangui in the mid-1980s, the disease was associated with
specific pathological lesions (spongiocyte-associated hepatitis) involving lympho-plasmocytoid
infiltrates, lesions of eosinophilic necrosis and massive macro- or micro-vacuolar steatosis,
giving cells a particular "morula-like" type and resulting in a high mortality rate [17,26]. Such
strain-associated lesions could be propagated in the woodchuck model [26]. Similar lesions
have been described in South American FH outbreaks [27,28] that were linked to HDV-3, usu-
ally associated with HBV-F, although HBV-A and HBV-D have also been implicated in Ama-
zonia [29,30]. In Bangui, the outbreak involved HDV-1, here associated with HBV-E. This
particular histopathological type of FH, associated with high mortality, was therefore not due
to a single HBV–HDV genotypic association. During the outbreak, it may be hypothesised
that a recent combination of different HDV-1 subgenotypes with the Twentieth Century-
introduced African HBV-E helper, rather than HBV-A or HBV-D, could have resulted in a
severe disease. Such an explanation was suggested in a study in Taiwan, where the spread of
HDV-1 to the Asian HBV-B and HBV-C genotypes resulted in more FH than the indigenous
HDV-2 [31]. Alternatively, there may be in equatorial rainforests some as yet unrecognised
cofactor that might increase the number of cases of fatal acute liver failure observed in both
CAR and Amazonia [25,32].
In this study, the potential role of specific HDV-1 strains or its HDAg protein in the patho-
logical lesions was looked for. We found no evidence of a specific HDV-1 fulminant associated
clade. Indeed, within the limits of the sequences obtained, the 1985 HDV-1 FH strains were
indistinguishable from asymptomatic-associated 2010 HDV-1 strains. Due to conservation con-
ditions since the outbreak, we were unfortunately unable to amplify full-length FH-associated
HDV genomes, even using many different approaches. This obviously cannot rule out some
specific virulence factors that could have been deduced from comparison of full-length genomes
between historical fulminant strains and recent asymptomatic-associated strains. The FH
strains and their HDAg sequences intermingle with strains isolated from 2010 asymptomatic
patients in CAR and with strains isolated elsewhere in Africa. The only exception corresponded
to one HDV clone that displayed a frameshift mutation at the 3’ terminus of the L-HDAg gene
that would eliminate the farnesylation signal of L-HDAg (Fig 2, FH27 clone 4). This may affect
virion assembly and perhaps induces intracellular retention of viral component that may accu-
mulate in infected cells. This variant was observed only once among 45 clones analysed from 12
FH-HDV strains. However, it can be hypothesised that mutants leading to intracellular reten-
tion may not easily egress from the infected-cell and might therefore be under-represented in
the serum. In addition, they may be potentially cytopathic for the infected hepatocytes. For
example, in HBV monoinfection of the human hepatocyte, retention of HBV-PreS1 mutants
results in specific pathological lesions known as "ground-glass" hepatocytes [33].
It is disappointing that vaccination against HBV is so uncommon among pregnant women
and students with a high education level, even among medical students. Neonatal vaccination
(DTP-HepB-Hib) has been practised in CAR since 2008, but coverage is still not universal
(http://www.gavi.org), in part due to civil unrest. At present, there is also no HBV immuno-
therapy nor immediate vaccination of neonates born outside hospitals, in the absence of quali-
fied midwifes [1]. Indeed, modelisation has suggested that the proportion of new chronic cases
arising from mother-to-child transmission may increase by up to 50% in 2030 [34]. Neonatal
anti-HBV vaccination is urgently needed, preferably including a dose as near as possible after
birth. Ideally, vaccination of as yet unprotected young populations should also be sustained
[1,34]. Meanwhile, at least 8% of the young population of Bangui is at risk for further HDV
superinfection and related liver damage. The situation outside of the nation’s capital is proba-
bly worse as a recent evaluation has estimated an HBsAg rural prevalence of 11.65% in CAR
[35]. The results of this study should clearly contribute to sensitise the health authorities to
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consider HBV and HDV infections as a major health challenge in the Central African Repub-
lic, and could lead to specific surveys, screening and medial actions among populations at risk
of HBV acquisition and/or transmission.
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focused on HBV A, D and E genotypes. HBV DNA was amplified and sequenced from 2010
samples (35 HBV PreC-C sequences). Alignment was manually corrected and submitted to dis-
tance models and Bayesian inference. Note that phylogenetic information of the PreC-C region
could not well differentiate HBV_D and HBV_E genotypes.
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